(SBRA) Sabra Healthcare REIT - Ratings and Ratios
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US78573L1061
SBRA: Nursing, Housing, Hospitals, Loans, Equity, Ventures, Facilities
Sabra Healthcare REIT Inc. (NASDAQ: SBRA) is a real estate investment trust focused on the healthcare sector, offering a diversified portfolio of properties and investments. As of September 30, 2024, the company owns 373 real estate properties held for investment, which includes 233 skilled nursing and transitional care facilities. These facilities are critical for patients requiring specialized care and rehabilitation services. Additionally, Sabra holds 39 senior housing communities under lease agreements and 68 senior housing communities managed by third-party operators, providing a mix of operational and leasing strategies. The portfolio also includes 18 behavioral health facilities and 15 specialty hospitals and other healthcare facilities, rounding out its exposure to various segments of the healthcare real estate market.
Geographically, Sabras properties span the United States and Canada, with a total of 37,793 beds and units. This scale provides significant diversification across markets and reduces reliance on any single region. Beyond its real estate holdings, Sabra has 14 investments in loans receivable, including three mortgage loans and 11 other loans, which contribute to its revenue streams. The company also holds five preferred equity investments and two stakes in unconsolidated joint ventures, further diversifying its capital allocation and income sources.
From a financial perspective, Sabra Healthcare REIT Inc. has a market capitalization of $3.97 billion as of the latest data. The stock trades with a trailing P/E ratio of 40.71 and a forward P/E of 8.71, indicating expectations for future earnings growth. The price-to-book (P/B) ratio stands at 1.45, while the price-to-sales (P/S) ratio is 5.81. These metrics provide insight into the companys valuation relative to its financial fundamentals and industry peers.
For investors and fund managers, Sabras diversified portfolio and exposure to various healthcare subsectors make it a notable player in the healthcare REIT space. The combination of owned properties, loans, and equity investments offers a balanced approach to generating returns. However, the high P/E ratio relative to forward earnings suggests that the market is pricing in significant growth expectations, which investors should carefully evaluate against the companys strategic position and industry trends.
Additional Sources for SBRA Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
SBRA Stock Overview
Market Cap in USD | 4,061m |
Sector | Real Estate |
Industry | REIT - Healthcare Facilities |
GiC Sub-Industry | Health Care REITs |
IPO / Inception | 2002-04-02 |
SBRA Stock Ratings
Growth 5y | 77.4% |
Fundamental | 38.0% |
Dividend | 63.1% |
Rel. Strength Industry | 20.3 |
Analysts | 4.07/5 |
Fair Price Momentum | 19.40 USD |
Fair Price DCF | 30.16 USD |
SBRA Dividends
Dividend Yield 12m | 7.24% |
Yield on Cost 5y | 24.49% |
Annual Growth 5y | -2.33% |
Payout Consistency | 89.7% |
SBRA Growth Ratios
Growth Correlation 3m | -31.1% |
Growth Correlation 12m | 74.4% |
Growth Correlation 5y | 59.2% |
CAGR 5y | 27.99% |
CAGR/Max DD 5y | 0.76 |
Sharpe Ratio 12m | 1.84 |
Alpha | 21.57 |
Beta | 0.51 |
Volatility | 29.45% |
Current Volume | 2619.5k |
Average Volume 20d | 2393.6k |
As of March 14, 2025, the stock is trading at USD 16.86 with a total of 2,619,466 shares traded.
Over the past week, the price has changed by +1.75%, over one month by +2.93%, over three months by -1.89% and over the past year by +27.81%.
Partly, yes. Based on ValueRay Fundamental Analyses, Sabra Healthcare REIT (NASDAQ:SBRA) is currently (March 2025) ok to buy, but has to be watched. It has a ValueRay Fundamental Rating of 37.98 and therefor a somewhat positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of SBRA as of March 2025 is 19.40. This means that SBRA is currently undervalued and has a potential upside of +15.07% (Margin of Safety).
Sabra Healthcare REIT has received a consensus analysts rating of 4.07. Therefor, it is recommend to buy SBRA.
- Strong Buy: 7
- Buy: 1
- Hold: 6
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, SBRA Sabra Healthcare REIT will be worth about 21 in March 2026. The stock is currently trading at 16.86. This means that the stock has a potential upside of +24.26%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 19.6 | 16.1% |
Analysts Target Price | 19.8 | 17.6% |
ValueRay Target Price | 21 | 24.3% |